Immunogenicity
Overall, the incidence of positive ADA results was low (≤5%) and decreased over time in both treatment arms. A total of 22 patients (12 patients in the BAT1706 arm and 10 in the EU‐bevacizumab arm), had negative ADA results at baseline and positive ADA results at the post‐baseline visit. No patients had neutralizing ADAs detected during the study. Overall, similar immunogenicity results were observed in the two treatment arms.